Medivir’s partner Infex Therapeutics signs a license agreement for the clinical development of MET-X in India

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces today that its partner Infex Therapeutics has signed an exclusive license agreement for the Indian market with Indian pharmaceutical company Venus Remedies Ltd for the clinical development of its metallo-beta-lactamase-inhibitor MET-X, targeting Gram-negative Enterobacterales.

Under the terms of the agreement, Venus will initially conduct a phase I trial for MET-X in combination with the beta-lactam antibiotic meropenem with healthy volunteers in India. Subject to the successful completion of the phase I trial, Venus will then conduct a combined phase II/III trial of MET-X/meropenem in patients with drug resistant Complicated Urinary Tract Infections (cUTIs), a common hospital acquired infection that can lead to life-threatening complications.
 
Infex will receive licence fee payments upon signature and completion of near-term milestones and tiered double-digit royalty payments on net sales of MET-X/meropenem in India by Venus. MET-X originates from Medivir’s Metallo Beta Lactamase (MBLI) program aimed at addressing the threat of resistant bacteria and was outlicensed in 2017 (the “Agreement”) to the AMR Centre (now Infex Therapeutics) in England. Under the terms of the Agreement, Medivir is entitled to a share of potential future revenue.
 
Read more: Press Release Infex. 

Datum 2025-02-25, kl 10:30
Källa MFN
Bifogade filer
Investera som eToros bästa investerare! Med eToros CopyTrader™, kan du automatiskt kopiera andra investerares beslut. Hitta investerare som du tror på och kopiera deras investeringar i realtid. Inga extra avgifter tas ut för funktionen.
Copy Trading innebär inte investeringsrådgivning. Värdet på dina investeringar kan gå upp eller ner. Du riskerar ditt kapital.